BMO Capital Maintains Outperform on Novo Nordisk, Maintains $163 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Novo Nordisk (NYSE:NVO) and keeps the price target at $163.
June 25, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Novo Nordisk and keeps the price target at $163.
The reaffirmation of an Outperform rating and a $163 price target by BMO Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100